Simcyp Limited, one of the Biofusion portfolio companies and a global leader in the in silico simulation and prediction of pharmacokinetics and drug-drug interactions in virtual patient populations, announced today that Dr Steve Toon has joined the Board as Executive Director.
Dr Toon has over twenty years experience of building businesses that provide high quality services to the pharmaceutical industry, especially with regard to experimental design and pharmacokinetic-pharmacodynamic data analysis.
As CEO of Medeval Limited he successfully grew the Company from approximately £1m turnover in 1993 to over £10m in 2003, a period of rapid growth that resulted in the Company being acquired by Icon plc in 2003.
Dr Toon will be responsible for cementing Simcyp’s reputation in modelling and simulation by expanding its global presence and product offering to all the leading pharmaceutical and biotechnology organisations.
Over recent years Simcyp has grown significantly through increased utilisation of its market leading software within the drug development processes by its existing customers, and by the acquisition of further major pharmaceutical organisations as clients. In addition, a number of university departments, prominent in pharmacokinetic and pharmacodynamic modelling, have incorporated Simcyp software into their teaching programmes. The Company also works closely with Drug Regulatory Authorities.
Commenting on the appointment, Professor Geoff Tucker, Chairman of Simcyp Limited and Head of the Academic Unit of Clinical Pharmacology at the University of Sheffield, said:
“We are delighted that an individual of such experience is joining the Board of Directors. I expect to be working closely with Steve over the coming years, as Simcyp expands into the simulation and prediction of further aspects of drug absorption and disposition and pharmacological and therapeutic effects.”